Lipoprotein particle subclass profiles among metabolically healthy and unhealthy obese and non-obese adults: Does size matter?

Atherosclerosis

Volumn 242, Issue 2, 2015, Pages 399-406

  Phillips, Catherine M ^a   Perry, Ivan J ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Dyslipidemia; Lipoproteins; Metabolically healthy obesity; Obesity

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOMETABOLIC RISK; CONTROLLED STUDY; FEMALE; HUMAN; INSULIN RESISTANCE; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; PARTICLE SIZE; PHENOTYPE; PRIORITY JOURNAL; ANTHROPOMETRY; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CHEMISTRY; CROSS-SECTIONAL STUDY; HEALTH STATUS; INFLAMMATION; IRELAND; LIFESTYLE; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED;

AGED; ANTHROPOMETRY; BLOOD PRESSURE; BODY MASS INDEX; CARDIOVASCULAR SYSTEM; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH STATUS; HUMANS; INFLAMMATION; INSULIN RESISTANCE; IRELAND; LIFE STYLE; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PHENOTYPE;

EID: 84939424952     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.07.040     Document Type: Article

References (51)

1. Kelly T., Yang W., Chen C.S., et al. Global burden of obesity in 2005 and projections to 2030. Int. J. Obes. 2005, 2008(32):1431-1437.
2. Mokdad A.H., Ford E.S., Bowman B.A., et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003, 289:76-79.
3. Van Gaal L.F., Mertens I.L., De Block C.E. Mechanisms linking obesity with cardiovascular disease. Nature 2006, 444:875-880.
4. Phillips C.M. Metabolically healthy obesity: definitions, determinants and clinical implications. Rev. Endocr. Metab. Disord. 2013 Sep, 14(3):219-227.
5. Ruderman N.B., Schneider S.H., Berchtold P. The "metabolically-obese", normal-weight individual. Am. J. Clin. Nutr. 1981, 34:1617-1621.
6. Karelis A.D., Rabasa-Lhoret R. Inclusion of C-reactive protein in the identification of metabolically healthy but obese (MHO) individuals. Diabetes Metab. 2008, 34:183-184.
7. Phillips C., Perry I.J. Does inflammation determine metabolic health status in obese and non-obese adults?. J. Clin. Endocr. Metab. 2013 Oct, 98(10). E1610-9.
8. Stefan N., Kantartzis K., Machann J., et al. Identification and characterization of metabolically benign obesity in humans. Arch. Intern Med. 2008, 168:1609-1616.
9. Wildman R.P., Muntner P., Reynolds K., et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch. Intern Med. 2008, 168:1617-1624.
10. Khan U.I., Wang D., Thurston R.C., et al. Burden of subclinical cardiovascular disease in "metabolically benign" and "at-risk" overweight and obese women: the Study of Women's Health across the Nation (SWAN). Atherosclerosis 2011, 217:179-186.
11. Kramer C.K., Zinman B., Retnakaran R. Are metabolically healthy overweight and obesity benign conditions? A systematic review and meta-analysis. Ann. Intern Med. 2013, 159:758-769.
12. Kwon B.J., Kim D.W., Her S.H., et al. Metabolically obese status with normal weight is associated with both the prevalence and severity of angiographic coronary artery disease. Metab. Clin. Exp. 2013, 62:952-960.
13. Hamer M., Stamatakis E. Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality. J. Clin. Endocrinol. Metab. 2012, 97:2482-2488.
14. Roberson L.L., Aneni E.C., Maziak W., et al. Beyond BMI: the "metabolically healthy obese" phenotype & its association with clinical/subclinical cardiovascular disease and all-cause mortality - a systematic review. BMC Public Health 2014, 14:14.
15. Garvey W.T., Kwon S., Zheng D., et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003, 52:453-462.
16. Magkos F., Mohammed B.S., Mittendorfer B. Effect of obesity on the plasma lipoprotein subclass profile in normoglycemic and normolipidemic men and women. Int. J. Obes. 2005, 2008(32):1655-1664.
17. Arsenault B.J., Lemieux I., Despres J.P., et al. HDL particle size and the risk of coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. Atherosclerosis 2009, 206:276-281.
18. Rizzo M., Pernice V., Frasheri A., et al. Atherogenic lipoprotein phenotype and LDL size and subclasses in patients with peripheral arterial disease. Atherosclerosis 2008, 197:237-241.
19. Jeyarajah E.J., Cromwell W.C., Otvos J.D. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin. Lab. Med. 2006, 26:847-870.
20. Telle-Hansen V.H., Halvorsen B., Dalen K.T., et al. Altered expression of genes involved in lipid metabolism in obese subjects with unfavourable phenotype. Genes Nutr. 2013, 8:425-434.
21. Iacobellis G., Ribaudo M.C., Zappaterreno A., et al. Small, dense low-density lipoprotein and C-reactive protein in obese subjects with and without other criteria for the metabolic syndrome. J. Clin. Lipidol. 2007, 1:599-604.
22. Kim M., Paik J.K., Kang R., et al. Increased oxidative stress in normal-weight postmenopausal women with metabolic syndrome compared with metabolically healthy overweight/obese individuals. Metab. Clin. Exp. 2013, 62:554-560.
23. Kim S., Lee H., Lee D.C., et al. Predominance of small dense LDL differentiates metabolically unhealthy from metabolically healthy overweight adults in Korea. Metab. Clin. Exp. 2014, 63:415-421.
24. Kearney P.M., Harrington J.M., Mc Carthy V.J., et al. Cohort profile: the Cork and Kerry diabetes and heart disease study. Int. J. Epidemiol. 2012 Oct, 42(5):1253-1262.
25. Meigs J.B., Wilson P.W.F., Fox C.S., et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J. Clin. Endocr. Metab. 2006, 91:2906-2912.
26. Craig C.L., Marshall A.L., Sjostrom M., et al. International physical activity questionnaire: 12-country reliability and validity. Med. Sci. Sports Exerc. 2003, 35:1381-1395.
27. Phillips C., Dillon C., Harrington J.M., McCarthy V.J.C., Kearney P.M., Fitzgerald A.P., Perry I.J. Defining metabolically healthy obesity: role of dietary and lifestyle factors. PloS One 2013 Oct 17, 8(10). e76188.
28. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
29. Shalaurova I., Connelly M.A., Garvey W.T., et al. Lipoprotein insulin resistance index: a lipoprotein particle-derived measure of insulin resistance. Metab. Syndr. Relat. Disord. 2014, 12:422-429.
30. El Harchaoui K., van der Steeg W.A., Stroes E.S., et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J. Am. Coll. Cardiol. 2007, 49:547-553.
31. Mora S., Otvos J.D., Rosenson R.S., et al. Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women. Diabetes 2010, 59:1153-1160.
32. Paynter N.P., Sesso H.D., Conen D., et al. Lipoprotein subclass abnormalities and incident hypertension in initially healthy women. Clin. Chem. 2011, 57:1178-1187.
33. Wurtz P., Raiko J.R., Magnussen C.G., et al. High-throughput quantification of circulating metabolites improves prediction of subclinical atherosclerosis. Eur. Heart J. 2012, 33:2307-2316.
34. Eshtiaghi R., Keihani S., Hosseinpanah F., et al. Natural course of metabolically healthy abdominal obese adults after 10 years of follow-up: the Tehran Lipid and Glucose Study. Int. J. Obes. 2005, 2014.
35. Gill J.M., Sattar N. Hepatic VLDL overproduction: is hyperinsulinemia or insulin resistance the culprit?. J. Clin. Endocrinol. Metab. 2011, 96:2032-2034.
36. Klop B., Elte J.W., Cabezas M.C. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients 2013, 5:1218-1240.
37. Gleeson A., Anderton K., Owens D., et al. The role of microsomal triglyceride transfer protein and dietary cholesterol in chylomicron production in diabetes. Diabetologia 1999, 42:944-948.
38. Phillips C., Bennett A., Anderton K., et al. Intestinal rather than hepatic microsomal triglyceride transfer protein as a cause of postprandial dyslipidemia in diabetes. Metab. Clin. Exp. 2002, 51:847-852.
39. Phillips C., Mullan K., Owens D., et al. Intestinal microsomal triglyceride transfer protein in type 2 diabetic and non-diabetic subjects: the relationship to triglyceride-rich postprandial lipoprotein composition. Atherosclerosis 2006, 187:57-64.
40. Ooi E.M., Watts G.F., Sprecher D.L., et al. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity. J. Clin. Endocrinol. Metab. 2011, 96:E1568-E1576.
41. Koba S., Hirano T., Murayama S., et al. Small dense LDL phenotype is associated with postprandial increases of large VLDL and remnant-like particles in patients with acute myocardial infarction. Atherosclerosis 2003, 170:131-140.
42. Taskinen M.R. Pathogenesis of dyslipidemia in type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 2001, 109(Suppl. 2):S180-S188.
43. Schreier L., Berg G., Zago V., et al. Kinetics of in vitro lipolysis of human very low-density lipoprotein by lipoprotein lipase. Nutr. Metab. Cardiovasc. Dis. 2002, 12:13-18.
44. Adiels M., Olofsson S.O., Taskinen M.R., et al. Diabetic dyslipidaemia. Curr. Opin. Lipidol. 2006, 17:238-246.
45. Taskinen M.R. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003, 46:733-749.
46. Hosseinpanah F., Barzin M., Sheikholeslami F., et al. Effect of different obesity phenotypes on cardiovascular events in Tehran Lipid and Glucose Study (TLGS). Am. J. Cardiol. 2011, 107:412-416.
47. Shin M.J., Hyun Y.J., Kim O.Y., et al. Weight loss effect on inflammation and LDL oxidation in metabolically healthy but obese (MHO) individuals: low inflammation and LDL oxidation in MHO women. Int. J. Obes. 2005, 2006(30):1529-1534.
48. Otvos J.D., Collins D., Freedman D.S., et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs high-density lipoprotein intervention trial. Circulation 2006, 113:1556-1563.
49. Otvos J.D., Mora S., Shalaurova I., et al. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J. Clin. Lipidol. 2011, 5:105-113.
50. Phillips C.M., Tierney A.C., Perez-Martinez P., et al. Obesity and body fat classification in the metabolic syndrome: impact on cardiometabolic risk metabotype. Obesity (Silver Spring MD) 2013, 21:E154-E161.
51. Perez-Martinez P., Alcala-Diaz J.F., Delgado-Lista J., et al. Metabolic phenotypes of obesity influence triglyceride and inflammation homoeostasis. Eur. J. Clin. Investig. 2014, 44:1053-1064.